Gloria Xue

Gloria Xue

Auto-generated profile, based on publicly available information

Gloria Xue

Indiana University School of Medicine Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXi Wu
Xi Wu
FSFei Shen
Fei Shen
GJGuanglong Jiang
Guanglong Jiang
GXGloria Xue
Gloria Xue
SPSantosh Philips
Santosh Philips
BSBryan Paul Schneider
Bryan Paul Schneider
Anthracyclines, widely used to treat breast cancer, have the potential for cardiotoxicity. We have previously identified and validated a germline single nucleotide polymorphism, rs28714259, associated with an increased risk of anthracycline-induced heart failure. We now provide insights into the mechanism by which rs28714259 might confer increased risk of cardiac damage. Using hiPSC-derived cardiomyocyte cell lines with either intrinsic polymorphism or CRISPR-Cas9-mediated deletion of rs28714259 locus, we demonstrate that glucocorticoid receptor signaling activated by dexamethasone pretreatment prior to doxorubicin exposure preserves cardiomyocyte viability and contractility in cardiomyocytes containing the major allele. Homozygous loss of the rs28714259 major allele diminishes dexamethasone’s protective effect. We further demonstrate that the risk allele of rs28714259 disrupts glucocorticoid receptor and rs28714259 binding affinity. Finally, we highlight the activation of genes and pathways involved in cardiac hypertrophy signaling that are blocked by the risk allele, suggesting a decreased adaptive survival response to doxorubicin-related stress.

1 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FSFei Shen
Fei Shen
GJGuanglong Jiang
Guanglong Jiang
SPSantosh Philips
Santosh Philips
LGLaura Gardner
Laura Gardner
GXGloria Xue
Gloria Xue
BSBryan P. Schneider
Bryan P. Schneider
Purpose: Paclitaxel is a widely used anticancer therapeutic. Peripheral neuropathy is the dose-limiting toxicity and negatively impacts quality of life. Rare germline gene markers were evaluated for predicting severe taxane-induced peripheral neuropathy (TIPN) in the patients of European ancestry. In addition, the impact of Cytochrome P450 (CYP) 2C8, CYP3A4, and CYP3A5 metabolizer status on likelihood of severe TIPN was also assessed. Experimental Design: Whole-exome sequencing analyses were performed in 340 patients of European ancestry who received a standard dose and schedule of paclitaxel in the adjuvant, randomized phase III breast cancer trial, E5103. Patients who experienced grade 3–4 (n = 168) TIPN were compared to controls (n = 172) who did not experience TIPN. For the analyses, rare variants with a minor allele frequency ≤ 3% and predicted to be deleterious by protein prediction programs were retained. A gene-based, case–control analysis using SKAT was performed to identify genes that harbored an imbalance of deleterious variants associated with increased risk of severe TIPN. CYP star alleles for CYP2C8, CYP3A4, and CYP3A5 were called. An additive logistic regression model was performed to test the association of CYP2C8, CYP3A4, and CYP3A5 metabolizer status with severe TIPN. Results: Cytochrome P450 oxidoreductase (POR) was significantly associated with severe TIPN (P value = 1.8 ×10−6). Six variants were predicted to be deleterious in POR. There were no associations between CYP2C8, CYP3A4, or CYP3A5 metabolizer status with severe TIPN. Conclusions: Rare variants in POR predict an increased risk of severe TIPN in patients of European ancestry who receive paclitaxel.

10 April 2024 in Cancer Reports
Verified
Journal Article
Open access
GXGloria R. Xue
Gloria R. Xue
MCMarie Clark
Marie Clark
CMClaudia Morr
Claudia Morr
JSJames E. Slaven
James E. Slaven
SQSyril Keena T. Que
Syril Keena T. Que
Background: Research from across the United States has shown that rurality is associated with worse melanoma outcomes. In Indiana, nearly a quarter of all residents live in rural counties and an estimated 2180 cases of melanoma will be diagnosed in 2023.Aims: This study examines how geographical location affects the stage of melanoma diagnosis in Indiana, aiming to identify and address rural health disparities to ultimately ensure equitable care.Methods and Results: Demographics and disease characteristics of patients diagnosed with melanoma at Indiana University Health from January 2017 to September 2022 were compared using Students t‐tests, Wilcoxon tests, chi‐squared or Fisher's exact tests. Patients from rural areas presented with more pathological stage T3 melanomas (15.0% vs. 3.5%, p < 0.001) in contrast to their urban counterparts. Additionally, rural patients presented with fewer clinical stage I melanomas (80.8% vs. 89.3%) and more clinical stage II melanomas (19.2% vs. 8.1%), compared to urban patients, with no stage III (p = 0.028). Concerningly, a significantly higher percentage of the rural group (40.7%) had a personal history of BCC compared to the urban group (22.6%) (p = 0.005) and fewer rural patients (78.0%) compared to urban patients (89.4%) received surgical treatment (p = 0.016).Conclusion: Patients from rural counties in Indiana have higher pathological and clinical stage melanoma at diagnosis compared to patients from urban counties. Additionally fewer rural patients receive surgical treatment and may be at higher risk of developing subsequent melanomas.

21 June 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
GXGloria R. Xue
Gloria R. Xue
IHIltefat H. Hamzavi
Iltefat H. Hamzavi
IKIndermeet Kohli
Indermeet Kohli
TMTasneem F. Mohammad
Tasneem F. Mohammad

23 September 2026 in The Clinical Teacher
Verified
Journal Article
Closed access
PDF file
BBBryan Bartnick
Bryan Bartnick
SSSana Shah
Sana Shah
SSStuart Sommers
Stuart Sommers
RWRaylee Warren
Raylee Warren
KKKhosla Khosla
Khosla Khosla
GXGloria Xue
Gloria Xue

17 May 2023
Verified
Other
Open access
FSFei Shen
Fei Shen
GJGuanglong Jiang
Guanglong Jiang
SPSantosh Philips
Santosh Philips
LGLaura Gardner
Laura Gardner
GXGloria Xue
Gloria Xue
BSBryan P. Schneider
Bryan P. Schneider
Supplemental table 1-Covariates analyses; Supplemental Table 2-Genotype frequency, variant allele frequency and Hardy-Weinberg Equilibrium (HWE) of variants in CYPs